Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NetApp Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while NetApp Inc. trades at $202.7 (market cap $38.95B). The key difference: NetApp Inc. is the larger of the two by market cap, and NetApp Inc. pays a 1.05% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NTAP | |
|---|---|---|
Market Cap | $29.60B | $38.95B |
Sector | Health | Technology |
52-Week High | $491.22 | $202.05 |
52-Week Low | $205.48 | $94.11 |
Enterprise Value | $27.56B | $38.10B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
NetApp (NTAP) trades at $202.00, up 1.65% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent acquisitions like JetStream Software and DataPelago enhancing its AI infrastructure. Earnings have consistently beaten estimates, with Q1 2026 EPS of $2.43 surpassing the $2.27 forecast. Revenue grew to $6.57B in 2025, and profitability remains robust with an 18.43% net income margin.
Outlook is positive due to strategic AI investments and earnings momentum, but risks include high valuation multiples (P/E of 31.26) and competitive pressures. Analyst consensus is mixed, with 36.62% buy ratings, though the $170.73 price target suggests caution. Investors should weigh growth prospects against valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
